Clinical Trials Logo
  1. Home
  2. Carcinoma, Neuroendocrine
  3. NCT02250885

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Carcinoma, Neuroendocrine Clinical Trial

Official title:
Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Clinical Trial Summary

Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.

Clinical Trial Description

Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors in adult patients age >/= to 18. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02250885
Study type Interventional
Source Gabrail Cancer Center Research
Contact
Status Completed
Phase Phase 2
Start date August 2014
Completion date August 2016
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04488263 - Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s
Completed NCT02205515 - An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis Phase 1/Phase 2
Completed NCT00353015 - Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06406465 - A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Phase 2
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Recruiting NCT06041516 - Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Phase 1
Completed NCT03012620 - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types Phase 2
Active, not recruiting NCT02487095 - Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers Phase 1/Phase 2
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Completed NCT00511862 - TheraSphere for the Treatment of Liver Metastases Phase 2
Terminated NCT02315625 - Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Phase 2
Recruiting NCT01876771 - A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours Phase 2
Recruiting NCT05237934 - Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Recruiting NCT02754297 - Personalized PRRT of Neuroendocrine Tumors Phase 2